Compositions for modulating tau expression
AssigneeBiogen MA Inc.
InventorsHolly Kordasiewicz, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
Claims80
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound, comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 consecutive nucleobases of any of the nucleobase sequences of SEQ ID NOs:
- 20-2565.
A compound, comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides and comprising a nucleobase sequence comprising at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 consecutive nucleobases complementary to an equal length portion of nucleobases:
- (i) 135783-135980 of SEQ ID NO:
- 1;
- (ii) 135853-135872 of SEQ ID NO:
- 1;
- (iii) 135783-135929 of SEQ ID NO:
- 1, or
- (iv) 135783-135914 of SEQ ID NO:
- 1.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A compound consisting of ISIS 613099;
- ISIS 613361;
- ISIS 613370;
- ISIS 623782;
- or ISIS 623996.
(canceled)
(canceled)
(canceled)
(canceled)
A compound consisting of a modified oligonucleotide according to the following formula:
- (A) Ges Aeo Teo Aeo Teo Tds Ads Tds mCds mCds Tds Tds Tds Gds Ads Geo mCeo mCes Aes mCe;
- wherein,
- A=an adenine,
- mC=a 5′-methylcytosine
- G=a guanine,
- T=a thymine,
- e=a 2′-O-methoxyethyl modified nucleoside,
- d=a 2′-deoxynucleoside, and
- o=a phosphodiester internucleoside linkage, and
- s=a phosphorothioate internucleoside linkage,
- (b) Aes mCeo Aeo mCeo Aeo mCds mCds Tds Tds mCds Ads Tds Tds Tds Ads mCeo Teo Ges Tes mCe;
- wherein,
- A=an adenine,
- mC=a 5′-methylcytosine
- G=a guanine,
- T=a thymine,
- e=a 2′-O-methoxyethyl modified nucleoside,
- d=a 2′-deoxynucleoside, and
- o=a phosphodiester internucleoside linkage, and
- s=a phosphorothioate internucleoside linkage;
- (c) Ges Geo Teo Teo Teo Tds mCds Ads Ads Ads mCds Ads mCds Ads mCds mCeo Teo Tes mCes Ae;
- wherein,
- A=an adenine,
- mC=a 5′-methylcytosine
- G=a guanine,
- T=a thymine,
- e=a 2′-O-methoxyethyl modified nucleoside,
- d=a 2′-deoxynucleoside,
- o=a phosphodiester internucleoside linkage, and
- s=a phosphorothioate internucleoside linkage;
- (d) mCes mCeo Geo Teo Tes Tds Tds mCds Tds Tds Ads mCds mCds Aeo mCeo mCes mCes Te;
- wherein,
- A=an adenine,
- mC=a 5′-methylcytosine
- G=a guanine,
- T=a thymine,
- e=a 2′-O-methoxyethyl modified nucleoside,
- d=a 2′-deoxynucleoside,
- o=a phosphodiester internucleoside linkage, and
- s=a phosphorothioate internucleoside linkage;
- or
- (e) Aes Aeo Teo Teo Tes Gds mCds Tds mCds Tds Tds Ads mCds Teo mCeo mCes mCes Ae;
- wherein,
- A=an adenine,
- mC=a 5′-methylcytosine
- G=a guanine,
- T=a thymine,
- e=a 2′-O-methoxyethyl modified nucleoside,
- d=a 2′-deoxynucleoside,
- o=a phosphodiester internucleoside linkage, and
- s=a phosphorothioate internucleoside linkage.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.